INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as a disease state characterized by airflow limitation that is not fully reversible (1). Cigarette smoking is the most important risk factor for the development of COPD. Although the dose-response relationship between cigarette smoking and pulmonary function is well-established, there is considerable variability in the reduction in FEV
among smokers with similar smoking exposures (2, 3) . The low percentage of variance in pulmonary function explained by smoking suggests that there could be genetic differences in susceptibility to the effects of cigarette smoking (4, 5) . In addition to genetic factors, other environmental determinants such as indoor biomass smoke exposure can be important risk factors for COPD (6) 
. A small percentage of COPD patients (estimated at 1-2%) inherit severe alpha-1 antitrypsin (AAT) deficiency, which proves that genetic factors can influence COPD susceptibility. The discovery of AAT deficiency was a major factor in the development of the ProteaseAntiprotease Hypothesis for COPD, which has been one of the prevailing models of disease pathogenesis for more than 40 years.
With the substantial impact of AAT deficiency on our understanding of COPD pathogenesis, it was natural to hope that the identification of other COPD susceptibility genes would lead to similar novel insights into COPD. Until recently, however, progress in the identification of additional genetic risk factors for COPD has been slow.
To facilitate the development of such research, a meeting of COPD genetics investigators was held on July [13] [14] 2010 in Boston. The goals of the meeting were: (1) (7) . A meta-analysis of 20 polymorphisms in 12 candidate genes involved in the protease-antiprotease balance and several antioxidant pathways showed that, after combining independent studies, many of these candidate genes had no association with COPD (8) . (15, 16) . One of these articles, from the CHARGE Consortium, also found evidence for association of FEV 1 /FVC with the FAM13A locus (15) , which has been strongly associated with COPD susceptibility (17) .
Another factor likely impeding the progress of identifying COPD susceptibility genes is the lack of accurate phenotypic characterization of this complex and heterogeneous disease. Airflow limitation determined by spirometry has been the most common approach to classify and monitor the disease. Structural changes of the lung including emphysema and small airway obstruction are the primary processes that affect lung function (9), but they are not easily discernable with the simple spirometric measures commonly used for phenotyping COPD. Recent advances in characterizing pathologic changes such as emphysema and remodeling of the small and large airways by quantitative analyses of image data from multidetector computed tomography (CT), together with physiological testing, have been helpful to differentiate COPD phenotypes (emphysema-predominant, airwaypredominant, or mixed)(10). Study populations that have chest CT data may help to better identify COPD-associated genetic variations (11). Other potentially relevant COPD
Moreover, several case-control studies from other European populations have replicated these findings by confirming significant associations to the chromosome 15q25 locus (CHRNA3/CHRNA5/IREB2) (18, 19) (27) . The genome-wide association study that identified FAM13A included three sets of COPD cases and smoking controls (17) . However, these studies are still underpowered to identify genetic determinants of small effect, and establishing a consortium of groups studying cigarette smokers may facilitate pooling large samples to identify genetic variants associated with COPD susceptibility. (35, 36) (30) . On the other hand, the identification of clinically relevant phenotypes should also lead to increased understanding of the underlying pathobiology that contributes to a particular phenotype (31) . Despite the huge advances in our understanding of the pathology of COPD in recent decades, there have been few attempts to link COPD pathologies to clinical COPD phenotypes (38) . Finally, it has been hypothesized that failure to identify COPD phenotypes may limit the power of therapeutic trials (39) as effective and safe therapy is likely to differ across phenotypes (31, 40 
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to a syndrome with multiple phenotypic expressions, thus changing (and challenging) current taxonomy of chronic airway diseases (37). Regarding disease etiology, the identification of non-genetic determinants of diseases will also benefit from an appropriate definition of phenotypes. It is also likely that the traditional approach to address heterogeneity (i.e., stratification by socio-demographic, clinical, or environmental factors) is likely to lead to a reduction in statistical power
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